SAB Biotherapeutics (SABS) Stock Price, News & Analysis

Company Overview

SAB Biotherapeutics, Inc. is a clinical‐stage biotechnology company focused on the development of fully human polyclonal antibodies for the prevention and treatment of infectious diseases and oncology indications. The company’s proprietary GenAb® platform leverages transchromosomic bovines—genetically engineered cattle capable of producing high‐potency, human immunoglobulins at scale. This innovative approach enables rapid response to emerging pathogens and the generation of therapeutic antibodies that mimic natural human immune responses.

The company’s pipeline includes several product candidates targeting viral threats and cancer. SAB-185, a fully human polyclonal antibody therapy for COVID-19, has advanced through clinical trials, while SAB-301 and SAB-181 have been developed against Middle East respiratory syndrome (MERS) and Zika virus, respectively. In the oncology arena, SAB-183 is being explored as an immunotherapy for solid tumors, reflecting SAB Biotherapeutics’ broader strategy to apply its platform across multiple therapeutic areas.

Founded in 2014 and headquartered in Sioux Falls, South Dakota, SAB Biotherapeutics operates a state‐of‐the‐art research and cattle production facility where herd management, antibody collection, and purification occur under one roof. The company’s leadership team is led by CEO Randall J. Lanier, Ph.D., whose experience in immunology and therapeutic development guides SAB’s strategic collaborations and regulatory engagements. SAB has established partnerships with government agencies and global biopharmaceutical firms to accelerate its research and development programs.

Looking ahead, SAB Biotherapeutics aims to expand its manufacturing capacity and broaden its pipeline through both internal discovery efforts and external collaborations. By harnessing the GenAb platform’s versatility, the company seeks to address unmet medical needs in infectious disease outbreaks and cancer immunotherapy, positioning itself as a leader in next‐generation antibody therapeutics.

Key Stats

• Today's Range: $2.31 to $2.84
• 50-Day Range: $1.69 to $2.69
• 52-Week Range: $1.00 to $5.01
• Volume: 48,021 shs
• Average Volume: 68,549 shs
• Market Capitalization: $23.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.25
• Consensus Rating: Buy

SAB Biotherapeutics Stock Analysis - MarketRank™

SAB Biotherapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 316th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

SAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

SAB Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($3.69) to ($2.98) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SAB Biotherapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SAB Biotherapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SAB Biotherapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.28% of the float of SAB Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SAB Biotherapeutics has recently decreased by 36.98%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SAB Biotherapeutics does not currently pay a dividend.

Dividend Growth

SAB Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.28% of the float of SAB Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in SAB Biotherapeutics has recently decreased by 36.98%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

SAB Biotherapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for SAB Biotherapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

27.77% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.82% of the stock of SAB Biotherapeutics is held by institutions.

SABS Stock Analysis - Frequently Asked Questions

How have SABS shares performed this year?

SAB Biotherapeutics' stock was trading at $3.79 at the start of the year. Since then, SABS shares have decreased by 33.0% and is now trading at $2.54.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) announced its quarterly earnings data on Friday, May, 9th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.44.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of SAB Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SAB Biotherapeutics investors own include ChargePoint (CHPT), PayPal (PYPL), Coinbase Global (COIN), Tesla (TSLA), Confluent (CFLT), CrowdStrike (CRWD) and Ford Motor (F).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SABS
• CIK: 1833214
• Web: www.bigcypressaccorp.com
• Phone: 605-679-6980
• Fax: N/A
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for SAB Biotherapeutics: $13.25
• High Price Target: $20.00
• Low Price Target: $10.00
• Potential Upside/Downside: +421.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.10 million
• Net Margins: N/A
• Pretax Margin: -9,067.72%
• Return on Equity: -105.14%
• Return on Assets: -69.24%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 1.69
• Quick Ratio: 1.69

Sales & Book Value

• Annual Sales: $1.32 million
• Price / Sales: 17.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.81 per share
• Price / Book: 0.90

Miscellaneous

• Outstanding Shares: 9,290,000
• Free Float: 6,709,000
• Market Cap: $23.60 million
• Optionable: Not Optionable
• Beta: 0.52